Binds Drug, Hapten, Hapten-carrier Complex, Or Specifically-identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 530/389.8)
-
Patent number: 10738334Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.Type: GrantFiled: September 22, 2016Date of Patent: August 11, 2020Assignee: Pfizer Inc.Inventors: Gregory Walter Hiller, Jeffrey Joseph Mitchell, Bhanu Chandra Mulukutla, Pamela Mary Pegman
-
Patent number: 9091684Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: GrantFiled: June 14, 2013Date of Patent: July 28, 2015Assignee: IDEXX Laboratories, Inc.Inventors: Murthy V. S. N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
-
Publication number: 20150118763Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: ApplicationFiled: November 7, 2014Publication date: April 30, 2015Inventors: STEPHEN PETER FITZGERALD, PAUL JOHN INNOCENZI, IVAN ROBERT McCONNELL, PHILIP ANDREW LOWRY, ELOUARD BENCHIKH
-
Publication number: 20150104818Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.Type: ApplicationFiled: December 19, 2014Publication date: April 16, 2015Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20150104806Abstract: The present invention relates to a biomarker for Parkinson's disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and/or development of Parkinson's disease. The invention also relates to use of the biomarker in clinical screening, assessment of prognosis, evaluation of drug treatments, drug screening or drug development in the field of Parkinson's disease and Parkinson's disease related disorders.Type: ApplicationFiled: April 10, 2013Publication date: April 16, 2015Applicant: University of DundeeInventors: Dario Alessi, Muratul Muqit
-
Publication number: 20150098935Abstract: In this application Is described a composition and method for Inducing In a subject anti-hapten antibodies without Inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described. In this application Is disclosed a synthetic liposome composition comprising liposomes (L) containing monophosphoryl lipid A (MPLA) [L(MPLA)] and an immunoconjugate comprising a carrier and a hapten. In one embodiment, the carrier is a 23 amino acid hydrophobic membrane proximal external region peptide (MPER) derived from the gp41 transmembrane protein of HIV-1 that spontaneously associates with the outer surface of bilayers of liposomes containing MPLA during liposome formation.Type: ApplicationFiled: February 8, 2013Publication date: April 9, 2015Applicant: Walter Reed Army Institute of ResearchInventors: Carl R. Alving, Gary R. Matyas, Arthur E. Jacobson, Fuying Li, Malliga R. Iyer, Kenner C. Rice, Kejun Cheng, Alexander Mayorov
-
Publication number: 20150093764Abstract: Blocking reagent compositions, as well as methods of making and using the same, are provided. Aspects of the composition include a blocking reagent that binds to the cell surface but does not specifically bind to a targeted first cell surface antigen. Also provided are system and kits that include the compositions.Type: ApplicationFiled: September 29, 2014Publication date: April 2, 2015Inventors: Jody Douglas Berry, Priyal Thakur, Mette Ejrnaes, Paul Waterman
-
Publication number: 20150086572Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: November 24, 2014Publication date: March 26, 2015Inventors: Michael Fung, Meisheng Lu, William N.C. Sun, Cecily R.Y. Sun
-
Publication number: 20150079109Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.Type: ApplicationFiled: March 2, 2014Publication date: March 19, 2015Applicant: BeiGene, Ltd.Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
-
Publication number: 20150071940Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: September 11, 2013Publication date: March 12, 2015Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Publication number: 20150064212Abstract: Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 ?, and methods of using the same.Type: ApplicationFiled: November 6, 2014Publication date: March 5, 2015Inventors: Benito Anton PALMA, Philippe Leff GELMAN
-
Publication number: 20150065693Abstract: There is provided a composition for prophylaxis or treatment of vascular or valvular calcification including a dipeptidylpeptidase-4 (DPP-4) inhibitor. The DPP-4 according to one exemplary embodiment of the present disclosure is expressed at an increased level when blood vessels and valves are calcified, and the calcification decreases remarkably upon administration of the DPP-4 inhibitor. Therefore, the DPP-4 inhibitor can be useful in treatment or prophylaxis of blood vessels or valves.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: Jae Kwan SONG, Eun Ju CHANG
-
Publication number: 20150064202Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: ApplicationFiled: April 2, 2013Publication date: March 5, 2015Applicant: NovelMed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 8969525Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: GrantFiled: November 9, 2010Date of Patent: March 3, 2015Assignee: Enzo Life Sciences, Inc.Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
-
Publication number: 20150056221Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Nicholas J. PAPADOPOULOS, Gavin THURSTON, Jessica R. KIRSHNER, Marcus P. KELLY, Thomas NITTOLI, Frank J. DELFINO
-
Publication number: 20150044235Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150044236Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150037813Abstract: The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).Type: ApplicationFiled: July 4, 2012Publication date: February 5, 2015Applicant: FUJIREBIO INC.Inventor: Yoshie GOISHI
-
Publication number: 20150038366Abstract: Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Inventors: Elouard Benchikh, Peter Fitzgerald, Ivan McConnell, Philip Lowry
-
Patent number: 8946392Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.Type: GrantFiled: June 14, 2011Date of Patent: February 3, 2015Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20150031749Abstract: A method of determining the Crohn's disease status of a subject comprising the steps of determining the level of miR-29 in a sample from said subject; and comparing the level of miR-29 determined in step (a) with one or more reference values.Type: ApplicationFiled: March 12, 2013Publication date: January 29, 2015Applicant: Isis Innovation LimitedInventor: Alison Simmons
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20150017183Abstract: Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.Type: ApplicationFiled: December 20, 2012Publication date: January 15, 2015Inventors: Nabil G. Seidah, Jianbing Zhang
-
Publication number: 20150004178Abstract: Anti-human sema4A antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4A antibodies can inhibit T cell proliferation and Th2 differentiation induced by IL-4, anti-CD3, anti-CD28 and recombinant sema4A.Type: ApplicationFiled: October 5, 2012Publication date: January 1, 2015Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun Liu, Ning Lu, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20140377282Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.Type: ApplicationFiled: November 1, 2012Publication date: December 25, 2014Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140377265Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.Type: ApplicationFiled: July 22, 2014Publication date: December 25, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
-
Publication number: 20140371101Abstract: PARylated proteins are enriched by treating cell lysates comprising PARylated proteins and DNA/RNA with an endonuclease that cleaves the DNA/RNA but not the PAR; and separating the PARylated proteins from the cleaved DNA/RNA. PARylation sites are labeled by eluting PARylated proteins from a PAR-affinity substrate with a nucleophilic amine exchange reactant, wherein the reactant labels PARylation sites of the proteins. Specific binding agents are identified by screening compounds for specific binding to a PARylated protein disclosed herein; and identifying one of the compounds as a specific binder of the protein. Antibodies which specifically bind PARylation sites are also disclosed.Type: ApplicationFiled: August 30, 2014Publication date: December 18, 2014Applicant: Board of Regents, The University of Texas SystemInventor: Yonghao Yu
-
Publication number: 20140370008Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.Type: ApplicationFiled: December 14, 2012Publication date: December 18, 2014Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
-
Publication number: 20140370521Abstract: This invention provides novel biomarkers for Niemann-Pick disease, type C (NPC). In an exemplary embodiment, the invention provides methods for identifying a subject as having NPC. In embodiments, the methods involve detecting the level of biomarker selected from the group comprising i) galectin-3 (LGALS3); ii) cathepsin D (CTSD); iii) LGALS3 and CTSD; and iv) LGALS3 and/or CTSD in combination at least one additional NPC associated biomarker in a sample obtained from the subject. In embodiments, the methods involve comparing the level of biomarker to a reference.Type: ApplicationFiled: December 14, 2012Publication date: December 18, 2014Inventors: Forbes D. Porter, III, Celine V. M. Cluzeau, Dawn E. Watkins-Chow, Christopher A. Wassif, William J. Pavan
-
Publication number: 20140370030Abstract: The present invention relates to isolated antibodies against human sPLA2-X and uses thereof.Type: ApplicationFiled: December 6, 2012Publication date: December 18, 2014Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
-
Publication number: 20140363450Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.Type: ApplicationFiled: August 12, 2013Publication date: December 11, 2014Applicant: MEDIRISTA BIOTECHNOLOGIES ABInventor: Johan FROSTEGÅRD
-
Publication number: 20140363436Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.Type: ApplicationFiled: June 27, 2014Publication date: December 11, 2014Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson
-
Publication number: 20140357517Abstract: The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection.Type: ApplicationFiled: May 9, 2012Publication date: December 4, 2014Applicant: Korea Institute of Radiological & Medical SciencesInventors: Kwang Seok Kim, Sang Woo Bae, Kyu Jin Choi, Eun Sook Kim
-
Publication number: 20140356380Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: ApplicationFiled: December 31, 2013Publication date: December 4, 2014Applicant: NOVIMMUNE S.A.Inventors: Greg Elson, Olivier Leger
-
Publication number: 20140349319Abstract: The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with an antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol.Type: ApplicationFiled: November 9, 2012Publication date: November 27, 2014Inventors: Ivan Petyaev, Valery Tsybezov
-
Publication number: 20140341927Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADS-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.Type: ApplicationFiled: May 27, 2014Publication date: November 20, 2014Applicant: Universite LavalInventors: Jean-Pierre Julien, Makoto Urushitani
-
Patent number: 8889138Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 11, 2010Date of Patent: November 18, 2014Assignees: Merck Sharp & Dohme Corp., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20140335103Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: ApplicationFiled: April 3, 2014Publication date: November 13, 2014Applicant: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Publication number: 20140336156Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3.Type: ApplicationFiled: July 18, 2014Publication date: November 13, 2014Inventors: NIVER PANOSIAN SAHAKIAN, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, JAMES Vincent FREEMAN, Qimu Liao, RAMON A. EVANGELISTA
-
Publication number: 20140314832Abstract: The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.Type: ApplicationFiled: August 2, 2013Publication date: October 23, 2014Applicant: Shanghai Pulmonary Hospital, Tongji University School of MedicineInventors: Huiping Li, Shanmei Wang
-
Publication number: 20140315227Abstract: The present invention relates to a method for diagnosing the degree of risk for preterm delivery or miscarriage, comprising measuring plasminogen activator inhibitor activity or level in plasma. Specifically, the present invention relates to: a method for diagnosing the degree of risk for preterm delivery or miscarriage, wherein when the plasminogen activator inhibitor activity or level is lower than those of normal pregnant woman, the degree of risk for preterm delivery or miscarriage is determined to be high; a kit for the diagnosis of the degree of risk for preterm delivery or miscarriage; and a pharmaceutical composition for the prevention of preterm delivery or miscarriage, comprising plasminogen activator inhibitor-1.Type: ApplicationFiled: November 15, 2012Publication date: October 23, 2014Inventors: Naohiro Kanayama, Kazuo Umemura, Takayuki Iwaki, Tetsumei Urano, Kotomi Ikuma
-
Publication number: 20140308272Abstract: According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG and/or HSPG.Type: ApplicationFiled: January 17, 2014Publication date: October 16, 2014Applicant: Sylvan Pharmaceuticals Pty, Ltd.Inventors: John Fergus McEwan, David Cullis-Hill, Martin Lyndale Windsor
-
Publication number: 20140308298Abstract: The present invention relates to a method for monitoring the tumor growth of an androgen-independent prostate cancer in a subject, by determining the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a prostate cancer cell obtained from said subject. The present invention also relates to a pharmaceutical composition comprising an anti-adrenomedullin antagonist antibody and/or at least one anti-adrenomedullin receptor antagonist antibody for treating an androgen-independent prostate cancer.Type: ApplicationFiled: November 2, 2012Publication date: October 16, 2014Applicants: UNIVERSITE D'AIX MARSEILLE, ASSISTANCE PUBLIQUE-HOPITAUX DE MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Institut National de la Sante et de la RechercheInventors: Caroline Berenguer-Daize, Pierre-Marie Martin, Kamel Mabrouk, Denis Bertin, L'Houcine Ouafik
-
Publication number: 20140302618Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.Type: ApplicationFiled: May 22, 2014Publication date: October 9, 2014Applicant: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Patent number: 8852953Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.Type: GrantFiled: July 16, 2010Date of Patent: October 7, 2014Assignee: Randox Laboratories Ltd.Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20140288275Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.Type: ApplicationFiled: March 11, 2014Publication date: September 25, 2014Applicant: Xencor, Inc.Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
-
Publication number: 20140287441Abstract: The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites.Type: ApplicationFiled: October 30, 2013Publication date: September 25, 2014Applicant: Randox Laboratories LimitedInventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
-
Patent number: 8841423Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.Type: GrantFiled: April 27, 2009Date of Patent: September 23, 2014Assignee: University of Iowa Research FoundationInventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, Jr., Jeffrey Robert Erickson
-
Publication number: 20140273023Abstract: The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens teased out of, i.e., derived from, the 5?-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20140271651Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken